1. Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293–307.
2. Tatapudi VS, Montgomery RA. Therapeutic modulation of the complement system in kidney transplantation: clinical indications and emerging drug leads. Front Immunol. 2019;10:2306.
3. Haas M. The significance of C4d staining with minimal histologic abnormalities. Curr Opin Organ Transplant. 2010;15(1):21–7.
4. Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol. 2015;5:674.
5. Das LK, Ide K, Tanaka A, Morimoto H, Shimizu S, Tanimine N, et al. Fc-gamma receptor 3A polymorphism predicts the incidence of urinary tract infection in kidney-transplant recipients. Hum Immunol. 2017;78(4):357–62.